Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Must Reads by Date

Must reads for theWeek ending January 20, 2019

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005

TAO: Nonwhite ethnicity, limb infection predict poor prognosis, Le Joncour A et al. Arthritis Rheumatol. 2018;70(Suppl 10): Abstract 1885

Ten years of anastrozole boosts disease-free survival, Ohtani S et al. SABCS 2018, Abstract GS3-04

Thrombolysis for acute ischemic stroke safe in GI malignancy, Inohara T et al. Circulation. 2018 Nov 6;138[suppl 1], Abstract A12291

More must reads

Must reads for theWeek ending January 13, 2019

Residents get less parental leave than faculty physicians, Magudia K et al. JAMA. 2018 Dec 11;320[22)]:2372-4; Varda B et al. JAMA. 2018 Dec 11;320[22]:2374-7

Open enrollment surge doubles plans selected , Centers for Medicare & Medicaid Services

Health care spending slowed but fewer insured, Martin A et al. Health Affairs. 2018. doi: 10.1377/hlthaff.2018.05085

Most physicians do not use telemedicine, Kane C et al. Health Affairs. 2018. doi: 10.1377/hlthaff.2018.05077

Physician burnout linked to EHRs, Gardner R et al. J Am Med Inform Assoc. doi: 10.1093/jamia/ocy145.

More must reads

Must reads for theWeek ending December 30, 2018

Expanded genetic analyses of myxofibrosarcomas may guide precision therapies, Ogura K et al. Nature Communications; 17 July 2018. https://doi.org/10.1038/s41467-018-03891-9

Malignant tenosynovial giant cell tumors appear to originate from synoviocytes, Al-Ibraheemi A et al. Modern Pathology; 11 Sept. 2018. https://doi.org/10.1038/s41379-018-0129-0

Type and rate of clonal evolution vary widely in sarcoma pathogenetic subgroups, Hofvander J et al. Nature Communications 10 Sept. 2018. https://doi.org/10.1038/s41467-018-06098-0

Increasing pannexin 1 levels might be a novel treatment for rhabdomyosarcoma , Xiang X et al. Oncogenesis; 21 Nov. 2018. https://doi.org/10.1038/s41389-018-0100-4

Emapalumab for primary hemophagocytic lymphohistiocytosis, Locatelli F et al. ASH 2018; Abstract LBA-6

More must reads

Must reads for theWeek ending December 23, 2018

Recurrence risk high regardless of VTE classification, Albertsen IE et al. Am J Med. 2018 Sep;131(9):1067-74.e4

Similar VTE rates seen with tofacitinib, TNF inhibitors, Desai RJ et al. Arthritis Rheumatol. 2018;70(suppl 10), Abstract L09

Study supports long-term survival in multiple myeloma subgroup, Usmani SZ et al. Blood Cancer J. 2018 Nov 23;8(12):123

Sickle cell: Daily hydroxyurea safe in African children, Tshilolo L et al. ASH 2018, Abstract 3

Apixaban surpasses DOACs in very elderly patients, Deitelzweig SB et al. Circulation. 2018 Nov 6;138[suppl 1]:A14900

More must reads

Must reads for theWeek ending December 16, 2018

Vanderbilt staging best for predicting overall survival in retroperitoneal sarcoma, Huggett B & Cates J. Modern Pathology; 5 Nov. 2018. https://www.nature.com/articles/s41379-018-0166-8

Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.

Luspatercept reduced transfusion burden in trial, List AF et al. ASH 2018, abstract 1

Gene therapy in severe hemophilia B, Reiss UM et al. ASH 2018, Abstract 491

Low rates of bleeding with DOAC interruption, Douketis J et al. ASH 2018, Abstract LBA-5

More must reads

Pages